A Phase I Study of Neihulizumab (AbGn-168H) in Patients With Steroid-refractory Acute Graft-versus-host Disease (Sr-aGvHD)
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2018
At a glance
- Drugs Neihulizumab (Primary)
- Indications Graft-versus-host disease
- Focus Pharmacokinetics
- Sponsors AbGenomics Corporation
- 01 Jun 2018 Status changed from not yet recruiting to recruiting.
- 27 Apr 2018 Planned initiation date changed from 1 Jan 2018 to 1 May 2018.
- 03 Nov 2017 New trial record